ZA200309557B - Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethy)-1-piperindinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride. - Google Patents

Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethy)-1-piperindinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride.

Info

Publication number
ZA200309557B
ZA200309557B ZA200309557A ZA200309557A ZA200309557B ZA 200309557 B ZA200309557 B ZA 200309557B ZA 200309557 A ZA200309557 A ZA 200309557A ZA 200309557 A ZA200309557 A ZA 200309557A ZA 200309557 B ZA200309557 B ZA 200309557B
Authority
ZA
South Africa
Prior art keywords
alpha
hydroxydiphenylmethy
piperindinyl
hydroxybutyl
hydrochloride
Prior art date
Application number
ZA200309557A
Other languages
English (en)
Inventor
M Satyanarayana Reddy
U V Bhaskara Rao
S Thirumalai Rajan
Original Assignee
Reddys Lab Ltd Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr filed Critical Reddys Lab Ltd Dr
Publication of ZA200309557B publication Critical patent/ZA200309557B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200309557A 2001-06-18 2003-12-09 Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethy)-1-piperindinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride. ZA200309557B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN484MA2001 2001-06-18

Publications (1)

Publication Number Publication Date
ZA200309557B true ZA200309557B (en) 2004-09-14

Family

ID=34566868

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200309557A ZA200309557B (en) 2001-06-18 2003-12-09 Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethy)-1-piperindinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride.

Country Status (20)

Country Link
EP (2) EP2261209A1 (fr)
JP (2) JP2005507374A (fr)
KR (1) KR20040015734A (fr)
CN (1) CN100390145C (fr)
AU (1) AU2001278094B2 (fr)
BG (1) BG108435A (fr)
BR (1) BR0117054A (fr)
CA (2) CA2450858C (fr)
CO (1) CO5540340A2 (fr)
CZ (1) CZ20033358A3 (fr)
EE (1) EE200400010A (fr)
HU (1) HUP0401546A2 (fr)
IL (2) IL159266A0 (fr)
MX (1) MXPA03011728A (fr)
NZ (1) NZ530118A (fr)
PL (1) PL367632A1 (fr)
RU (1) RU2269516C2 (fr)
SK (1) SK15372003A3 (fr)
WO (1) WO2002102777A2 (fr)
ZA (1) ZA200309557B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392303A4 (fr) * 2001-04-09 2005-01-26 Teva Pharma Polymorphes de chlorhydrate de fexofenadine
JP2005532356A (ja) 2002-06-10 2005-10-27 テバ ファーマシューティカル インダストリーズ リミティド 塩酸フェキソフェナジンの多型体ｘｖｉ
GB0319935D0 (en) * 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
US20050256163A1 (en) * 2004-04-26 2005-11-17 Ilan Kor Crystalline forms of fexofenadine hydrochloride and processes for their preparation
ITMI20041143A1 (it) * 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
ITMI20041568A1 (it) * 2004-07-30 2004-10-30 Dipharma Spa "polimorfi di fexofenadina base"
WO2006037042A1 (fr) * 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Forme de cristal de fexofenadine et ses processus de preparation
WO2007007347A1 (fr) * 2005-07-07 2007-01-18 Wockhardt Limited Procédé industriel de préparation du chlorhydrate de fexofénadine avec un minimum de produits secondaires
US20090306135A1 (en) 2008-03-24 2009-12-10 Mukesh Kumar Sharma Stable amorphous fexofenadine hydrochloride
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
EP2354125A1 (fr) * 1994-05-18 2011-08-10 Aventisub II Inc. Formes polymorphiques anhydres et hydratées de derivés de piperidine antihistaminiques
US6153754A (en) * 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
IN191492B (fr) 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
GB0018691D0 (en) * 2000-07-28 2000-09-20 Rolabo Sl Process

Also Published As

Publication number Publication date
BG108435A (en) 2004-12-30
CZ20033358A3 (en) 2004-04-14
MXPA03011728A (es) 2004-07-08
JP2005507374A (ja) 2005-03-17
BR0117054A (pt) 2004-07-27
NZ530118A (en) 2007-05-31
EE200400010A (et) 2004-02-16
CN100390145C (zh) 2008-05-28
IL159266A (en) 2010-11-30
RU2269516C2 (ru) 2006-02-10
KR20040015734A (ko) 2004-02-19
WO2002102777A2 (fr) 2002-12-27
JP2008094848A (ja) 2008-04-24
PL367632A1 (en) 2005-03-07
EP1399422A2 (fr) 2004-03-24
CA2646802A1 (fr) 2002-12-27
WO2002102777A3 (fr) 2003-02-27
AU2001278094B2 (en) 2006-01-12
RU2004101045A (ru) 2005-06-27
CO5540340A2 (es) 2005-07-29
CN1518540A (zh) 2004-08-04
CA2450858C (fr) 2009-04-07
HUP0401546A2 (hu) 2004-12-28
EP2261209A1 (fr) 2010-12-15
WO2002102777A8 (fr) 2003-10-30
CA2450858A1 (fr) 2002-12-27
IL159266A0 (en) 2004-06-01
SK15372003A3 (sk) 2004-08-03

Similar Documents

Publication Publication Date Title
ZA200309557B (en) Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethy)-1-piperindinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride.
AU2002360561A1 (en) 4-substituted piperidines, and methods of use thereof
SI1870100T1 (sl) Metansulfonat etil estra heksiloksikarbonilamino imino metil fenilamino metil metil H benzimidazol karbonil piridin il amino propionske kisline
NO20061562L (no) Anvendelse av 1- [4-(5-cyanindol-3yl)butyl ] -4-(2-karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptable salter
DE60038481D1 (de) Kristalline form des (r)-2-äää3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridinylümethylüsulfinylü-1h-benzimidazols
NO20042861L (no) N-(3-butyn-1-yl)-N-hydroksyurea
AU2003260744A1 (en) 1, 4- substituted piperidine derivatives and use thereof as base-inhibitors in treatment of alzheimer's disease
WO2001094313A3 (fr) Modification cristalline
AU2002352962A1 (en) Novel-n-(4-(1h-imidazol-1-yl)-2-fluorophenyl)-3-(trifluoromethyl)-1-h-pyrazole-5-carboxamides as factor xa
HUP0201673A3 (en) Process for the preparation of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl]-alpha, alpha-dimethylbenzeneacetic acid
AU1018801A (en) Use of 3,4-substituted piperidines
IS7901A (is) 4-(2-Fenýloxýfenýl)-píperidín eða -1,2,3,6-tetrahýdrópýridín afleiður sem serótónín endurupptöku hindrar
WO2002100847A3 (fr) Inhibiteur du facteur xa
ATE369342T1 (de) 2,5-disubstituierte 3-mercaptopentansaure
YU61503A (sh) Nova so benzoilgvanidina
WO2005113526A3 (fr) Metabolites de 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
AU2003244922A1 (en) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating pulmonary fibrosis
IL152570A0 (en) A process for the preparation of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-alpha, alpha-di methylbenzeneacetic acid
AU2002310949A1 (en) Method of producing N-substituted 2,6-dialkyl morpholines
MXPA01005769A (es) Nuevas formas cristalinas del acido (3s-trans) -2[3,4-dihidro -4-hidroxi -3-(enilmetil)-2h -1-benzofiran -7-il] -4- (trifluorometil) benzoico.
MXPA03006534A (es) Metodo para obtener (3-ciano-1h-indol-7-il)-(4(4- fluorfenetil)-piperazin-1-il)-metanona y sus sales.
WO2003010160A3 (fr) Composes chimiques
AU6562600A (en) Crystalline modification iii of n-(4-(5-dimethylamino-naphthaline-1-sulfonylamino)-phenyl)-3 -hydroxy-2,2-dimethyl-propionamide
AU2669001A (en) Cyclopropyl-anellated 3-(4,5-dihydroisoxazol-3-yl)-substitued benzoylpyrazoles
AU2003259394A1 (en) Preparation of 1-(4-(2-methoxy-phenyl)-piperazin-1-yl)-3-(2,6-dioxopiperidin-1-yl) propane hydrochloride